References
- Koro CE, Bowlin S, Bourgeois N, Fedder D. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with Type 2 diabetes: a preliminary report. Diabetes Care27(1), 17–20 (2004).
- Rave K, Bott S, Heinemann L et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care28(5), 1077–1082 (2005).
- Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and phamacodynamics of inhaled insulin. Clin. Pharmacokinet.43(12), 781–801 (2004).
- Strack TR. Inhaled human insulin. Drugs Today42(4) 208 (2006).
- Becker RH, Sha S, Frick AD et al. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care29, 277–282 (2006).
- Fountaine RJ, Milton A, Wei G et al. Effects of albuterol and fluticasone on inhaled human insulin (Exubera®) pharmacokinetics in patients with mild-to-moderate asthma. Diabetes55(Suppl. 1), A112 (2006) (Abstract 469-P).
- Rosenstock J, Zinman B, Murphy LJ et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in Type 2 diabetes: a randomized control trial. Ann. Intern. Med.143(8), 549–558 (2005).
- Skyler JS; Inhaled Insulin Phase 2 Study Group. Long-term sustained efficacy and safety of inhaled insulin after 4 years of continuous therapy. Diabetologia47(1 Suppl.), A311 (2004).
- Quatttrin TA, Belanger A, Bohannon JHV, Schwartz SL. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with Type 1 diabetes. Diabetes Care27, 2622–2627 (2004).
- Skyler JS, Weinstock RS, Raskin P et al. Use of inhaled insulin in a basal/bolus insulin regimen in Type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care28, 1630–1635 (2005).
- Hollander PA, Blonde L, Rowe R et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with Type 2 diabetes: results of a 6 month, randomized, comparative trial. Diabetes Care27(10), 2356–2362 (2004).
- Cefalu WT, Skyler JS, Kourides IA et al. Inhaled human insulin treatment in patients with Type 2 diabetes mellitus. Ann. Intern. Med.134, 203–207 (2001).
- Fineberg SE, Kawabata T, Finco-Kent D et al. Antibody response to inhaled insulin in patients with Type 1 or Type 2 diabetes. An analysis of initial Phase II and III inhaled insulin (Exubera) trials and two-year extension trial. J. Clin. Endocrinol. Metab.90(6), 3287–3294 (2005).
- Freemantle N, Blonde L, Duhot D et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with Type 2 diabetes. Diabetes Care28, 427–428 (2005).
- Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care26(3), 917–932 (2003).
Websites
- Data & Trends National Diabetes Surveillance System Insulin and Diabetes Medication Use Number of Adults with Diabetes by Diabetes Medication Status, United States, 1997–2003 www.cdc.gov/diabetes/statistics/meduse/fig1.htm
- Rosenstock J. Two-Year Data on EXUBERA Abstract American Diabetes Association 66th Scientific Sessions, June 9–13, 2006, Washington, DC, USA www.medscape.com/viewarticle/540927?rss
- Pfizer Inc. (Exubera®) inhaled insulin package insert Jan 2006 www.fda.gov/cder/foi/label/2006/021868lbl.pdf